Please assess the completion status of the following clinical trial:

Trial Title: Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for all patients:~* ≥ 18 years of age~* Able to comply with study and follow-up requirements~Inclusion Criteria for high risk patients:~* elected to undergo prophylactic salpingo-oophorectomy~* fertile patients must use effective non-hormonal contraception~* agreed to use a nonhormonal means of contraception before surgery~* serum bilirubin ≤ 1.0 x Upper Limit Normal (ULN), alkaline phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) ≤ 2.5 x ULN~* serum creatinine ≤ 1.5 x ULN~* granulocyte count ≥ 1500/μL~* platelet count ≥ 75,000/μL~* hemoglobin ≥ 9 g/dL~* adequate complete blood count~* At high risk for developing ovarian cancer, as defined by any of the following:~* Breast Cancer carried a BRCA1 or BRCA2 deleterious mutation, a Lynch syndrome mutation, and/or defined by a family history of: 1 first-degree relative with epithelial ovarian cancer, ≥1 first-degree female relative with breast cancer when ≤40 years old, ≥1 first-degree female relative with breast cancer when ≤50 years old, male relative with breast cancer, and/or family history of breast cancer or ovarian cancer.~Inclusion Criteria for low risk patients:~* planning to undergo oophorectomy for a medical indication~* did not fulfill criteria for high risk of developing ovarian cancer~Exclusion criteria:~* liver disease, current alcohol abuse, or cirrhosis~* pregnancy or lactation~* current use of hormone therapy~* active treatment for cancer~* recent, current, or planned participation in another experimental drug study~* breast cancer within the past 5 years~* significant traumatic injury within the past 6 months~* major surgery within the past 6 months~* any disease, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates the continued use of an investigational drug or that may render the patient at high risk from treatment complication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 83 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: ACTIVE_COMPARATOR): Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.
- High Risk Arm (Type: NO_INTERVENTION): High risk patients underwent risk-reducing salpingo-oophorectomy.
- Low Risk Arm (Type: NO_INTERVENTION): Low risk patients underwent salpingo-oophorectomy for a medical indication.

Based on this trial design, predict the completion outcome and termination type (if applicable).